Warburg Pincus [1] is buying $75 million worth of Inspire Pharmaceuticals' stock. The private equity group paid a five percent premium for the shares, which immediately pushed up the value of the company's stock by 14 percent. For Inspire, the fresh injection of capital will help fund late-stage studies while launching the newly-approved AzaSite [2] for bacterial conjunctivitis.
- check out the release [3]
- read the AP report [4]
Related Articles:
Inspire wins feds approval of eye infection therapy. Report [2]
Inspire licenses anti-infective for $13M upfront. Report [5]
Side effects prompt Inspire to shutter trial. Report [6]
Inspire shares plunge after FDA finds data insufficient. Report [7]
Links:
[1] http://www.fiercebiotech.com/story/warburg-pincus-agrees-to-pay-4.5b-for-bausch-lomb/2007-05-16
[2] http://www.fiercebiotech.com/story/inspire-wins-feds-approval-of-eye-infection-therapy/2007-04-30
[3] http://www.fiercebiotech.com/node/7685
[4] http://www.forbes.com/feeds/ap/2007/07/18/ap3925857.html
[5] http://www.fiercebiotech.com/story/inspire-licenses-anti-infective-for-13m-upfront/2007-02-16
[6] http://www.fiercebiotech.com/story/side-effects-prompt-inspire-to-shutter-trial/2006-08-08
[7] http://www.fiercebiotech.com/story/inspire-shares-plunge-after-fda-finds-data-insufficient/2005-12-02